Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine.
Emerg Infect Dis
; 30(6): 1282-1283, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38669121
ABSTRACT
Because novel SARS-CoV-2 variants continue to emerge, immunogenicity of XBB.1.5 monovalent vaccines against live clinical isolates needs to be evaluated. We report boosting of IgG (2.1×), IgA (1.5×), and total IgG/A/M (1.7×) targeting the spike receptor-binding domain and neutralizing titers against WA1 (2.2×), XBB.1.5 (7.4×), EG.5.1 (10.5×), and JN.1 (4.7×) variants.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Neutralizantes
/
Inmunidad Humoral
/
Glicoproteína de la Espiga del Coronavirus
/
Vacunas contra la COVID-19
/
SARS-CoV-2
/
COVID-19
/
Anticuerpos Antivirales
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Emerg Infect Dis
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos